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Abstract
Background: In Tyrol, Austria, the existing system of spontaneous mammography screening was switched in 2007
to an organised program by smoothly changing the established framework. This process followed most EU
recommendations for organised mammography screening with the following exceptions: women aged 40-49 are
part of the target population, screening is offered annually to the age group 40-59, breast ultrasound is available as
an additional diagnostic tool, and double reading has not yet been implemented. After a pilot phase the program
was rolled out to all of Tyrol in June 2008. The aim of this study was to analyse the performance of the organised
screening system by comparing quality indices and recommended levels given in the well-established EU guidelines.
Methods: Working from the results of the pilot phase, we extended the organised mammography system to all counties
in Tyrol. All women living in Tyrol and covered by compulsory social insurance were invited for a mammography, in the
age group 40-59 annually and in the age group 60-69 biennially. Screening mammography was offered mainly by
radiologists in private practice, with further assessment performed at hospitals. Using the screening database, all well-
established performance indicators were analysed and compared with accepted/desired levels as per the EU guidelines.
Results: From June 2008 to May 2009, 120,440 women were invited. Per 1000 mammograms, 14 women were
recalled for further assessment, nine underwent biopsy and four cancer cases were detected. Of invasive breast
cancer cases, 32.3% and 68.4% were ≤ 10 mm and ≤ 15 mm in size, respectively, and 79.2% were node-negative.
The positive predictive value for further assessment and for biopsy was 25.9% and 39.9%, respectively. Estimated
two-year participation rate was 57.0%. In total, 14 interval cancer cases were detected during one year of follow-up;
this is 18.4% of the background incidence rate.
Conclusions: In Tyrol, Austria, an organised mammography screening program was implemented in a smooth
transition from an existing spontaneous screening system and was completely rolled out within a short time. The
high level of performance already seen in the pilot phase was maintained after rollout, and improvements resulting
from the pilot phase were affirmed after one year of complete rollout.
Background
Breast cancer is the leading cause of female cancer
death in all industrialised countries (and also world-
wide), and the breast is also the leading incident cancer
site for females [1]. Therefore, screening methods for
breast cancer are of greatest public health importance.
A recently published Cochrane Review, which assessed
the effect of mammography screening for breast cancer
on mortality and morbidity concluded that screening is
likely to reduce breast cancer mortality [2].
In 2006, in Tyrol, Austria, the decision was made to
change the existing spontaneous mammography screening
system to an organised program while, on the one hand,
making best possible use of the mammography screening
network established over the previous fifteen years and, on
the other hand, following most EU recommendations for
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conducted in two central counties of Tyrol covering 40%
of the population from June 2007 to May 2008 [3], the
organised system was completely rolled out to all of Tyrol
in June 2008. It was possible to establish a country-wide
mammography screening program in a very short time,
which differs only in the following aspects from the EU
guidelines [4]: women aged 40-49 are part of the target
population, screening is offered annually in the age group
40-59, breast ultrasound is available as an additional diag-
nostic tool, and double reading has not yet been
implemented.
To our knowledge, some European countries still have
no organised mammography screening program or are in
the process of planning to set up such a system [5,6].
Therefore, the Tyrolean experience can make an impor-
tant contribution to deciding how to switch a health sys-
tem with spontaneous mammography screening to an
organised screening program that meets well-accepted
quality guidelines.
It was the aim of this study to analyse the performance
of the organised mammography screening system after
complete rollout to all counties in Tyrol by measuring
the quality indicators recommended by the EU guidelines
[4] and to determine whether the high quality observed
in the pilot phase could be affirmed after rollout.
Methods
Study population, invitation
The target population in the first year of complete rollout
from June 2008 to May 2009 included all women aged
40 to 69 living in Tyrol and covered by compulsory social
insurance, which is more than 97% of the population (per-
sonal communication). The main health insurance carrier
sent out personal invitation letters to all the women in the
target population in the month in which the women had
their birthday: women aged 40-59 annually, and women
aged 60-69 biennially. As women aged 60-69 and living in
the two central counties of Tyrol where the pilot phase
was conducted had already been invited in the pilot year,
this group of women was not invited again in the first year
of rollout (Figure 1). Mammography screening was offered
by 22 screening units; thirteen of them were run by
radiologists in private practice and nine by hospital outpa-
tient departments. The mammogram was read by only
one radiologist; ultrasound (US) was offered to women at
the radiologist’s discretion. Assessment was offered by
nine hospital radiology units in the study area and
included clinical inspection, mammography, US, magnetic
resonance imaging (MRI) and biopsy as needed. Women
were recalled for assessment either directly by the screen-
ing unit or by the general practitioner. The one large
assessment unit at Innsbruck Medical University Hospital
works closely with a breast cancer centre that was
EUSOMA-certified in March 2010 [7]. All radiologists
participating in the program underwent training and
received ÖRG (Austrian Radiology Association) certifica-
tion. In the median, private radiologists and hospital units
performed 3234 and 1639 mammograms per year, respec-
tively. The mammography screening system has been
described in more detail elsewhere [3].
Data collection
All mammography units registered basic information in
a database. Screening and assessment information was
transferred to a central database after pseudonymising
the woman’s social insurance number [3]. In addition,
data on tumour characteristics were collected by the
Cancer Registry of Tyrol.
Statistical analysis
The screening and assessment data were realised as
STATA datasets. Linkage between screening data,
assessment data and Cancer Registry data is based on
the pseudonym number. We reported numbers and pro-
portions as defined in the EU guidelines [4]. For some
indices, population-based rates were computed using the
official population data supplied by Statistics Austria. No
statistical testing was applied. All reporting was done
with STATA Version 11 [8].
Performance indicators were reported from all screens
in women aged 40-69 between June 2008 and May 2009.
Participation rate was calculated following a cohort
approach: we counted every woman only once in the
observation period, which was either one year or two
years. Due to the fact that nearly half of women aged 40 to
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Figure 1 Mammography screening system Tyrol, invitation scheme.
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Page 2 of 759, who attend screening regularly, do not return for
screening in the first year although they are invited
annually, we computed for that age group also a two-year
participation rate, meaning an observation period of two
years.
Data on all mammography investigations performed in
Tyrol are transferred to the screening database. A small
portion (5.9%) of the women refused consent for data
transfer to the screening database and we therefore
receive only an empty dataset. Of all other mammogra-
phy data, 76% belong to the screening population. By
assuming this same proportion of 76% for the empty
dataset, we calculated a proportion of 4.5% to be added
to the observed participation rate accounting for empty
datasets describing real numbers of mammography
screening investigations.
As spontaneous mammography screening was already
introduced to Tyrol in the early 1990s, the underlying
background incidence rate (BIR) was defined by years of
diagnosis 1988-1990.
This study was conducted in conformity with the Hel-
sinki Declaration [9]. The project was approved by the
Ethics Committee of Innsbruck Medical University.
Results
From June 2008 to May 2009 120,440 women in the target
population were invited; this excluded women aged 60-69
and living in the two central counties where the pilot
phase was conducted, who fell in the biennial screening
interval for that age group and were thus not invited again
in this first year of complete rollout (Figure 1). The
observed one- and two-year participation rates were 31.6%
and 52.5%, respectively (Table 1). Participation was higher
in younger women. For example, the two-year observed
participation rate was 55.1% in women aged 40-49 versus
50.3% in women aged 50-69.
Performance indicators were analysed for all screens
performed in the first year of rollout, namely 42,834
screens. Of the women 75.5% underwent additional US
(80.9% in women aged 40-49). Breast density (ACR 3/4)
was the reason for additional US in 52.7% and 39.6% of
women aged 40-49 and 50-69, respectively (Table 2).
Per 1000 screens, 14 women were recalled for further
assessment. Screening result was unknown for a total of
98 cases (0.2% of screens). Per 1000 screens, nine under-
went biopsy. Of all biopsies, 86% were core biopsies and
3% open biopsies (13 cases). We observed 3.6 screen-
detected cancers per 1000 screens or a total of 153
breast cancer cases, of which 9.2% were diagnosed as in
situ cancers. The positive predictive value (PPV) was
25.9% for further assessment, 39.9% for total biopsy and
45.8% for core biopsy. PPV was lower in age group 40-
49 (18.7%, 31.3% and 34.9% for further assessment, total
biopsy and core biopsy, respectively). Performance para-
meters are summarised in Table 3.
Of 139 invasive cancers diagnosed in screening, four
changed to “in situ cancer” after final diagnosis. Two
invasive cancer cases did not undergo surgery because
of metastatic disease. Finally, three invasive cancer cases
underwent neoadjuvant therapy and it was not possible
to identify preoperative staging.
Of all invasive cancers detected and finally proven,
32.3% and 68.4% showed tumour size ≤10 mm and ≤15
mm, respectively. Lymph node involvement was
observed in 20.8% of invasive cancer cases (Table 4).
For invasive cancers, 90.6% of further assessments
were carried out within five working days after screening
and 87.1% and 90.1% underwent surgery within ten days
and 15 days after decision to operate, respectively. For
all cases except invasive cancers, 73.7% underwent
assessment within five working days and 17.1% after ten
or more working days (Table 5).
We observed a total of 14 interval cancer cases within
one year after screening in all of Tyrol, five in age group
40-49, giving an interval cancer rate of 20.8% and 17.8% of
the background incidence rate for age groups 40-49 and
50-69, respectively (Table 6). Table 7 shows the results for
the most important quality indicators of the EU guidelines
[4] restricted to age group 50-69. Given that the organised
system was introduced after more than a decade of spon-
taneous mammography screening in Tyrol, as reference
values we chose the accepted and desired ranges of EU
quality indicators for subsequent rounds. Most of the indi-
cators were within the EU range, except the participation
rate (54.8% vs. the limit of 75%), the proportion of II+ can-
cers (33.3% vs. the limit of 25%), the proportion of invasive
cancers (91.2%, this is slightly above the limit of 90%) and
the proportion of cases that underwent surgery within
≤ 15 working days after decision to operate (87.3%, this is
slightly below the limit of 90%).
Discussion
We analysed performance after one year of rolling out
an organised mammography screening program to all
counties in Tyrol. The organised program was estab-
lished in a smooth transition from an existing sponta-
neous mammography screening system, instead of
setting up a completely new screening system, and was
Table 1 Invitation system: Number of women invited and
participation rates
40-49 50-69 Total (40-69)
Women invited 56,888 63,552 120,440
Observed one-year participation rate 32.6% 30.6% 31.6%
Estimated one-year participation rate 37.1% 35.1% 36.1%
Observed two-year participation rate 55.1% 50.3% 52.5%
Estimated two-year participation rate 59.6% 54.8% 57.0%
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Page 3 of 7previously tested in a pilot phase comprising 40% of the
target population [3]. Although not all EU recommenda-
tions were followed, most quality indicators are in the
range of accepted/desired levels given by the EU guide-
lines [4]. The only parameter that clearly missed the EU
guidelines was the participation rate: the two-year
participation rate was 57% as compared to the 75%
recommended by the EU guidelines. In our opinion, a
cumulative participation rate of 57% after two years of
observation looks successful when compared to neigh-
bouring countries [10-12]. Nevertheless, it is not the
goal we aimed for.
Table 2 Additional ultrasound at screening
40-49 50-69 Total
Ultrasound following mammography screening 15,126 (80.9%) 17,196 (71.2%) 32,322 (75.5%)
Reason for ultrasound:
Breast density (ACR 3/4) 7,971 (52.7%) 6,806 (39.6%) 14,777 (45.7%)
Equivocal finding 1,801 (11.9%) 2,318 (13.5%) 4,119 (12.7%)
Other 5,354 (35.4%) 8,072 (46.9%) 13,426 (41.5%)
Table 3 Performance parameters
40-49
1) 50-69
1) Total
1)
Recall for further assessment rate [per 1000 screens] and number of recalls
2) 14.6 (273) 13.2 (318) 13.9 (591)
Intermediate screening test recommended in six months 18.9 (354) 12.1 (292) 15.1 (646)
Screening result unknown
3) 2.8 (52) 1.9 (46) 2.3 (98)
Biopsy rate [per 1000 screens] 8.7 (163) 9.1 (220) 8.9 (383)
Cancer detection rate [per 1000 screens] 2.7 (51) 4.2 (102) 3.6 (153)
Invasive 2.5 (46) 3.9 (93) 3.3 (139)
In situ 0.3 (5) 0.4 (9) 0.3 (14)
Proportion of in situ cases 9.8% 8.8% 9.2%
Ratio screening breast cancer detection rate vs. background incidence rate
4) 2.1 2.0 2.0
PPV assessment 18.7% (51/273) 32.1% (102/318) 25.9% (153/591)
PPV biopsy 31.3% (51/163) 46.4% (102/220) 39.9% (153/383)
1) Rates were rounded to one decimal; numbers in brackets are numbers of cases (i.e. recall rate, biopsy rate, cancer detection rate). PPV is rounded to one
decimal; numbers in brackets are detailed numbers for computing PPV.
2) For one case assessment was recommended, but performed at an institution outside the screening system.
3) Cases with BI-RADS 0 without assessment were treated as unknown.
4) Background incidence rate defined by years of diagnosis 1988-1992.
Table 4 Characteristics of invasive cancer cases
40-49 50-69 Total
Tumour size (mm): N = 133 13; 4-25 12; 1-35 13; 1-35
Median; range
Tumour size (mm):
< = 10 mm 14 (32.6%) 29 (32.2%) 43 (32.3%)
< = 15 mm 28 (65.1%) 63 (70.0%) 91 (68.4%)
11-20 mm
1) 23 (53.5%) 42 (46.7%) 65 (48.9%)
> 20 mm 6 (14.0%) 19 (21.1%) 25 (18.8%)
Lymph node involvement 8 (18.6%) 19 (21.8%)
1) 27 (20.8%)
Staging according to UICC
I 30 (69.8%) 55 (61.8%) 85 (64.4%)
II 13 (30.2%) 31 (34.8%) 44 (33.3%)
III 3 (3.4%) 3 (2.3%)
Notes: Of 139 invasive cancer cases, four cases were finally “in situ"; two invasive cancer cases did not undergo surgery because of metastatic status. Three cases
were without lymph node status because of neoadjuvant therapy and because we could not identify pretherapeutic TNM stage.
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Page 4 of 7The strengths of the Tyrolean breast cancer screening
program are its implementation and performance: we
were able to set up an organised population-based screen-
ing program within a short time with minimal additional
resources that shows good performance. In summary, the
recall for further assessment rate and the biopsy rate are
fairly low, PPV was good as compared to other programs,
only few open biopsies were performed, and despite the
lack of double reading the interval cancer rate of 20% of
the underlying BIR is rather good as compared to other
programs [10,13-15].
However, this study has several weaknesses.F i r s t ,u p
to now we have not implemented double reading as
recommended in the EU guidelines. Interestingly, perfor-
mance parameters and especially interval cancer rate
showed that also without double reading an acceptable
quality level was achieved. One reason could be the
extensive use of additional US, about three of four
women underwent additional US. The real benefit of US
in a population-based mammography screening program
is currently under discussion and has to be further evalu-
ated [16,17]. Calculation of the interval cancer rate is reli-
ant on the completeness of the Cancer Registry of Tyrol,
which covers the target population. Completeness of inci-
dence data in general has been shown to be very good
[3,18]. In order to be able to analyse interval cancer rates
for the screening program the timeliness of registration
of breast cancer was improved, and linkage between can-
cer registry data and screening data is based on pseudo-
nymising the social insurance number, which is read
electronically. In the meantime, we have also assessed
interval cancer in the time window 12 to 23 months for
the pilot phase of the Tyrol program, see [3], and found
five interval cancer cases in age group 40-49 (55% of BIR)
and seven interval cancer cases in age group 50-69 (33%
of BIR), data not shown.
Second, the average number of screens read by a radiol-
ogist in Tyrol per year (about 3200) does not meet the EU
recommendation of 5000. A recent publication [19]
showed that annual numbers below 5000 can still provide
good sensitivity and acceptable false-positive rates.
Third, we used BI-RADS categories instead of a single
yes/no rule for recall for further assessment. Some radiolo-
gists still use BI-RADS 0 (meaning unclear result) in a
small number of cases (0.2% of all screens), and 15 per
1000 screens were invited to an intermediate screening
test six months following a BI-RADS 3 screening result.
Due to this inconsistency, the current program includes
the following modifications: BI-RADS 0 is no longer
allowed and BI-RADS 3 is strictly associated with recall
for further assessment.
Many countries have run a mammography screening
program for decades or for a shorter time. On the other
hand, there are still some countries with no organised
Table 5 Waiting times
Invasive cancers
40-49 50-69 Total
Screening to assessment
≤ 5 wd 40 (87.0%) 86 (92.5%) 126 (90.6%)
6-10 wd 3 (6.5%) 3 (3.2%) 6 (4.3%)
> 10 wd 3 (6.5%) 4 (4.3%) 7 (5.0%)
Decision to operate to date of therapy
≤ 10 wd 42 (93.3%) 73 (83.9%) 115 (87.1%)
11-15 wd 1 (2.2%) 3 (3.4%) 4 (3.0%)
16-30 wd 1 (2.2%) 4 (4.6%) 5 (3.8%)
> 30 wd 1 (2.2%) 7 (8.0%) 8 (6.1%)
All screens except those ending in invasive cancers
40-49 50-69 Total
Screening to assessment
≤ 5 wd 162 (72.3%) 166 (75.1%) 328 (73.7%)
6-10 wd 17 (7.6%) 24 (10.9%) 41 (9.2%)
> 10 wd 45 (20.1%) 31 (14.0%) 76 (17.1%)
wd: working days
Table 6 Interval cancer rate within first year
40-49 50-69 Total
Interval cancer rate per 100,000 screens (number of cases in brackets) 26.7 (5) 37.3 (9) 32.7 (14)
Proportion of background incidence rate
1) (in percent) 20.8% 17.8% 18.4%
1) based on years of diagnosis 1988-1990
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Page 5 of 7breast cancer screening program. For those countries
thinking of or already in the process of introducing a
mammography screening program, our manner of intro-
ducing an organised program can serve as one how-to
example. In our opinion, the greatest difference between
our approach and other approaches, especially compared
to Germany, is the smooth transition made from an
existing spontaneous program to an organised popula-
tion-based screening. We made use of the network of
screening and assessment units that had already been set
up during spontaneous screening and added an invitation
system covering the entire population of Tyrol, a screen-
ing database that allows quality indices to be monitored
and a well-defined training program for both screening
and assessment units. With this strategy we were able to
meet most EU quality indices within a very short time.
Conclusions
In Tyrol, Austria, an organised mammography screening
system realised in a smooth transition from an existing
spontaneous screening system was rolled out in a short
time. The high level of performance already observed in
the pilot phase has not changed after the first year of com-
plete rollout. Improvements suggested during the pilot
phase were affirmed after rollout: it will be necessary to
concentrate on efforts to improve the participation rate,
introduce double reading, change the rule for BI-RADS 3,
and reduce the number of additional ultrasound exams.
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